All posts by Tim Link

Portfolio Review – Healthcare – Actavis

The Schwab Profile – Actavis (ACT) (price of stock is $296.54 as of 6/9/15) is a global, integrated specialty pharmaceutical company. The Company focuses on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter

Video: Rare Interview with Johnson and Johnson CEO Alex Gorsky

Alex Gorsky,  CEO of Johnson and Johnson,  discusses new drugs in the company’s pipeline,  promising results in oncology  and defending the company’s franchise.   Part 1  Part 2